Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:37:02.508Z.
Calculation as of: 2026-10-06T18:37:02.508Z.
Quote observation: 2026-10-06T18:34:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$125.37M
PS Ratio
4.31
TTM Avg
11.00
3Y Avg
311.63
5Y Avg
311.63
Market Cap
$127.07M
PS Ratio
37.44
TTM Avg
108.18
3Y Avg
108.18
5Y Avg
108.18
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $125.14M | N/A | N/A | N/A | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.37M | 4.31 | 11.00 | 311.63 | 311.63 |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.07M | 37.44 | 108.18 | 108.18 | 108.18 |
| Entera Bio Ltd. (ENTX)vs › | $127.17M | N/A | 643.32 | 865.94 | 547.59 |
| BGM Group Ltd. (BGM)vs › | $119.26M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | 28.10 | 25.82 | 87.76 | 78.89 |
| Seer, Inc. (SEER)vs › | $121.01M | 8.74 | 7.14 | 7.75 | 61.78 |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A | N/A | N/A | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $130.20M | 11.80 | 33.16 | 22.27 | 22.27 |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.48M | 90.25 | 500.86 | 500.86 | 500.86 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
